Navigation Links
OptiNose Completes Series C-1 Financing

YARDLEY, Pa., Aug. 4, 2014 /PRNewswire/ -- OptiNose, a specialty pharmaceutical company, announced today that it has completed a Series C-1 round of financing led by existing investors. Since obtaining Series C financing in 2010, OptiNose has successfully developed AVP-825, a product that, once approved, will be used for the treatment of migraines. OptiNose out-licensed the North American marketing rights for AVP-825 to a partner and jointly submitted a New Drug Application with the U.S. FDA earlier this year. In parallel with that program, OptiNose has actively pursued the significantly larger development program of OPN-375, a new product with applications in the treatment of serious chronic nasal inflammatory diseases.

Sriram Venkataraman, a director of OptiNose and a partner at Avista Capital Partners, said, "We are pleased with the progress of the clinical development programs to date and are committed to supporting the OptiNose team further as they execute on their clinical and commercial priorities, especially the development of the major new product OPN-375."

"With this latest round of financing, we are well-positioned to take the actions necessary to maximize the potential of our second product, OPN-375, which we believe will be a transformational breakthrough product in a large market with significant unmet need," said Peter Miller, Chief Executive Officer of OptiNose. "I am proud of the OptiNose team and the progress we have made together to date. I am also very excited about the future, as we continue late-phase clinical research, prepare commercial supply chain, and engage in pre-commercialization efforts around OPN-375."

About OPN-375

OPN-375 uses OptiNose's patented technology to deliver a highly effective and well-understood topical steroid medication (fluticasone) into the nasal cavity in a deeply distributed manner that improves upon prior approaches to intranasal drug delivery. Available data, including two published Phase II trials, suggest that OPN-375 has the potential to be a breakthrough product that could be transformational in the treatment of serious chronic nasal inflammatory diseases like chronic rhinosinusitis with nasal polyps. A global late-phase clinical program for nasal polyps, comparable in scale to that required for a new molecular entity and enrolling over 1,500 patients, is underway. Enrollment is ongoing or completed in all planned trials. OptiNose is also working to ensure that other critical enablers of future OPN-375 product success, including a launch-ready supply chain and other appropriate pre-commercial efforts, are in place to bring the product to market immediately following regulatory review.

About OptiNose

OptiNose is a specialty pharmaceutical company built around a unique nasal delivery platform. The company is driven by an experienced, world-class team with expertise including drug and device development, product manufacturing and commercialization. OptiNose is focused on using its patented technology to identify and develop reduced-risk assets that create significant commercial value by offering meaningful new clinical benefits to patients and healthcare systems. The OptiNose closed-palate

Bi-Directional™ Breath Powered™ technology platform provides dramatically enhanced delivery of drug into the nasal cavity compared to current approaches. When used to deliver select medications for diseases where this type of delivery is important to targeting, efficacy or safety, this innovative technology platform can be a critical enabler for the development of valuable new products. OptiNose has an exciting pipeline of these assets for the treatment of diseases with significant unmet need. OptiNose was founded in 2000 and has corporate offices in Yardley, PA (USA), Oslo, Norway, and the United Kingdom.

Investors in OptiNose include Avista Capital Partners, WFD Ventures LLC and Entrepreneurs Fund LP. For more information, please visit

About Avista Capital Partners

Avista Capital Partners is a leading private equity firm with approximately $6 billion under management and offices in New York, Houston and London. Founded in 2005, Avista makes controlling or influential minority investments in growth-oriented energy, healthcare, communications & media, industrials, and consumer businesses. Through its team of seasoned investment professionals and industry experts, Avista seeks to partner with exceptional management teams to invest in and add value to well-positioned businesses.

Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. OptiNose Receives Grant to Fund Nose-to-Brain Research in Autism Spectrum Disorders
2. OptiNose mottar stipend for nese-til-hjerne-forskning innen spektrumet for autismesykdommer
3. MGC Diagnostics Corporation Completes Acquisition of MediSoft SA
4. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytrens Contracture In Japan
5. Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427
6. Glide Pharma Completes Successful Proof-of-Concept Study with Novel Solid Dose Formulation of Octreotide
7. TeraMedica Completes one of the Worlds Largest VNA Installations in New South Wales, Australia
8. Seres Health Completes Enrollment in a Clinical Study for SER-109 in Recurrent Clostridium difficile Infection and Announces Positive Preliminary Data
9. Verus Healthcare Completes Over 85 Acquisitions
10. Virobay Completes $8 Million Series B Preferred Stock Financing
11. Valeant Pharmaceuticals Completes Sale Of Filler And Toxin Assets To Galderma
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015   HeartWare International, Inc . ... miniaturized circulatory support technologies that are revolutionizing the treatment ... Chief Executive Officer Doug Godshall is scheduled ... Annual Healthcare Conference on December 1, 2015 at 3:00 ... in New York . ...
(Date:11/24/2015)... BERN, Switzerland , November 24, 2015 /PRNewswire/ ... Biomedical Engineering Research of the University of ... Diabetes and Clinical Nutrition of the Bern University Hospital ... exclusive collaboration to develop a novel generation artificial pancreas. ... delivery of insulin for diabetic patients with the unequalled ...
(Date:11/24/2015)... 2015 F1000Workspace - a research ... it was launched just six months ago. --> ... platform for scientists - since it was launched just six ... loaded on to F1000Workspace - a research collaboration, ... was launched just six months ago. --> ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... American Specialty ... Program have announced their endorsement of the Medical Fitness Network (MFN), a ... proud to have the MFN as one of our endorsed organizations,” said ASH ...
(Date:11/24/2015)... N.Y. (PRWEB) , ... November 24, 2015 , ... Autism ... Tuesday, the global movement driven by social media and the generosity of people around ... then encourage their social media networks to give – and share the personal stories ...
(Date:11/24/2015)... ... November 24, 2015 , ... World Patent ... Blending, a household invention that revolutionizes the vending machine industry by providing healthy ... is worth $2 billion," says Scott Cooper, CEO and Creative Director of World ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Robert Yeager ... Trend Report . Throughout the past year there have been multiple breakthroughs and challenges ... During this transition, PharmMD has enabled their customers and partners to stay ahead of ...
(Date:11/24/2015)... ... November 24, 2015 , ... Dehydration, defined as a loss of body water ... the hot sun, and heat stroke and death will quickly follow. A normal human ... Kleyne. Every cell, system and structure requires water to function properly. Kleyne, who believes ...
Breaking Medicine News(10 mins):